tbuckley/cabot-search huggingface dataset:
Abstract 4380: CD133/prominin-1 modulates epithelial-mesenchymal transition, stemness and tumorigenicity of oral squamous cell carcinoma-derived cancer initiating
Authors: Yu-Syuan Chen, Jeng-Fan Lo
Journal: Cancer Research (2011)

Abstract Background: Oral squamous carcinoma cell (OSCC) is a lethal cancer with clinical, pathological, phenotypical and biological heterogeneity. Tumor initiating cells (TICs), which are responsible for tumor growth and coupled with epithelial-mesenchymal transition (EMT), have been identified. We have also identified the subpopulation of oral cancer derived tumor initiating cells (OC-TICs), and observed the upregulation of CD133 in OC-TICs. Others demonstrate that CD133 is phosphorylated by Src and Fyn tyrosine kinases. However, the molecular function of CD133 in OC-TICs remains unclear. Herein we determined the critical role of CD133, an important TICs marker, in the maintenance of stemness characteristics and tumorigenic phenotype of OC-TICs. Methods: Stable overexpression and knockdown of CD133 expression in OSCCs and OC-TICs was achieved by lentiviral-mediated system. Consequently, we elucidated the epithelial-mesenchymal transition, the stemness properties and tumorigenicity of OSCCs and OC-TICs with CD133 down-regulation or overexpression, respectively. Consequently, we investigated the role of Src and and Fyn tyrosine kinases in CD133 mediated signaling pathway. Results: Stable over-expression of CD133 induced epithelial-mesenchymal transition, enhanced tumorigenicity and enhanced the TICs properties in OSCCs. In contrast, lentiviral knockdown of CD133 significantly reduced the self-renewal ability, side population cells, and stemness genes in OC-TICs. Additionally, down-regulation of CD133 enhanced the differentiation capability but inversely diminished “stemness” gene expression of OC-TICs. Of note, knockdown of CD133 lessened tumorigenicity of OC-TICs both in vitro and in vivo. Furthermore, over-expression of CD133 increased phosphorylation of Src and Erk1/2. Conclusion: We showed that CD133 contributes to the epithelial-mesenchymal transition and the maintenance of stemness and tumorigenicity of OC-TICs. In addition, Src and Erk1/2 activation was involved in CD133 modulating phenotype. Overall, silencing CD133 might be a potential therapeutic target for OSCC by eliminating TICs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4380. doi:10.1158/1538-7445.AM2011-4380
A2.24 Activation of the NLRP3 inflammasome by an endogenous TLR2 ligand in rheumatoid arthritis
Authors: M Connolly, T McGarry, M Biniecka, DJ Veale, U Fearon
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background/Objectives</h3> The inflammasome is a large multiprotein complex which plays a key role in innate immunity by mediating the production of pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18. The most characterised inflammasome is NLRP3, activation of which results in numerous biological effects associated with infection, inflammation and autoimmune processes. While the inflammasome has traditionally been thought to regulate infection and inflammation, impaired mitochondrial metabolism may mediate this process. In this study we examined the interplay between the inflammasome and mitochondrial function following TLR2 activation. <h3>Methods</h3> Mitochondrial mutagenesis was assessed by Random Mutation Capture Assay. Reactive oxygen species were measured by cellular detection assay. Primary RASFC and whole <i>ex vivo</i> synovial tissue were stimulated with a TLR2 agonist, PAM3CYSK4, in the presence of absence of N-Acetyl Cysteine (NAC). IL-1β and IL-18 expression was examined by PCR. NLRP3 expression was assessed by real-time PCR and western blot. To establish whether A-SAA activates TLR, human embryonic kidney (HEK) -TLR2 or -TLR4 cells were cultured in the presence of A-SAA and NFκB luciferase activity was examined. In parallel, the effect of A-SAA on RASFC function was examined in the presence of a specific neutralising anti-TLR2 mAb (1 μg/ml) and matched IgG isotype control Ab (1 μg/ml). RASFC proliferation, adhesion, chemokine expression and migration were assessed by proliferation assays, flow cytometry, Taqman PCR, ELISA and wound repair assays. <h3>Results</h3> PAM3CYSK4 significantly induced mitochondrial mutagenesis and reactive oxygen species in RA synovial explants cultures and fibroblasts (p &lt; 0.05). TLR2 activation increased transcript levels of inflammasome and pro-inflammatory mediators including IL-1, IL-18 and NLRP3. Furthermore, activation of TLR2 induced IL-6, IL-8, IL-1, IL-18 at a protein level, effects which were significantly inhibited in presence of NAC, an ROS inhibitor (all p &lt; 0.05). Additionally, we demonstrated that A-SAA is an endogenous TLR2 ligand since it induced TLR2 mediated NF-κB lucifearse activity (p &lt; 0.05), with no effect observed for NFκB in HEK-TLR4 cells. A-SAA significantly induced NLRP3 mRNA and protein expression. In parallel, A-SAA induced RASFC proliferation, ICAM-1 expression and migration, all of which were significantly inhibited in the presence of anti-TLR2 (all p &lt; 0.05), further confirming its role as an endogenous TLR2 ligand. <h3>Conclusion</h3> TLR2 induces mitochondrial dysfunction which plays a key role in the regulation of downstream inflammasome activation. TLR2-induced pro-inflammatory effects in RA may be mediated by endogenous secretion of A-SAA from the synovium at the site of inflammation.
SAT0222 Hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, particularly in antiphospholipid positive patients:
Authors: G. Law, L. Magder, H. Fang, M. Petri
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> Past studies, mostly cross-sectional, have found a reduction in thrombosis in systemic lupus erythematosus (SLE) patients taking hydroxychloroquine. We examined the relationship between hydroxychloroquine and other medications with thrombosis in a large prospective SLE cohort. <h3>Methods</h3> We studied 1795 SLE patients (56% Caucasian, 37% African American, 93.3% female, mean age 37.0±12.5) with no previous thrombosis prior to entry in the cohort. The primary outcome was first thrombotic event (arterial or venous). Univariate analysis and multivariable modelling were used to examine associations between prednisone, hydroxychloroquine, and NSAID use with the risk of thrombosis. <h3>Results</h3> A total of 193 thrombotic events were observed over 10,508 person-years of follow-up (rate 18.4/1000 person-years). In the multivariable model controlling for age, traditional cardiovascular risk factors, and SLE disease activity, significant predictors for thrombosis included current prednisone dose (&gt;20 mg/day, HR 4.2, p&lt;0.0001) and Aspirin use (HR 1.9, p=0.0009). Hydroxychloroquine use remained protective for thrombosis (HR 0.7, p=0.012). Subgroup analysis revealed that the protective effect of hydroxychloroquine was stronger in antiphospholipid antibody positive patients (HR 0.6, p=0.0080) than among antiphospholipid antibody negative patients (HR 0.8, p=0.48). <h3>Conclusions</h3> Current prednisone dose was found to be a significant independant predictor of thrombosis in SLE, after adjustment for disease activity. Current hydroxychloroquine use decreased the risk of thrombosis in this prospective cohort, particularly in those with positive antiphospholipid antibodies. Aspirin use was not protective, likely due to the bias of indication. <h3>Disclosure of Interest</h3> None Declared
Neuropathic Foot Lesions in Diabetes Mellitus
Authors: C. Cabell Bailey, Howard F. Root
Journal: New England Journal of Medicine (1947)

JOINT changes associated with diseases of the central nervous system were first described by Charcot. At first these changes were considered peculiar to tabes dorsalis and syringomelia, but with extensive use of x-ray examination, similar changes have been found in other conditions. Leprosy may produce a similar picture, as may injury to a peripheral nerve, as described by Weinberg1 in soldiers injured in World War I. Bone lesions similar to those in Charcot's joints have also been reported in association with diabetes mellitus.2 3 4 5 6 7 This report deals with neuropathic foot lesions that occur in patients with diabetes mellitus and are attributed . . .
SAT0130 Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohn’s disease:
Authors: G.R. Burmester, R. Panaccione, K.B. Gordon, M.J. McIlraith, A. Lacerda
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> As long-term treatment with anti-tumour necrosis factor (TNF) drugs becomes accepted practice, the risk assessment of prolonged administration requires understanding of anti-TNF long-term safety. Rates of adverse events (AE) in patients (pts) treated with anti-TNF therapy can vary across therapeutic indications due to differences in disease-inherent risks, comorbidities, and use of concomitant immunosuppressant drugs. <h3>Objectives</h3> To assess and compare adalimumab's (ADA) long-term safety profile through nearly 12 years of clinical trial exposure in 6 pt populations. <h3>Methods</h3> Safety data from pts treated with ADA in 71 global clinical trials in rheumatoid arthritis (RA), juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis (Ps), and Crohn's disease (CD) were analyzed. Events per 100 patient-years (PYs) were calculated using events reported after first dose through 70 days after last dose. Standardized incidence rates (SIR) for malignancies were calculated using a National Cancer Institute database. Standardized mortality rates (SMR) were calculated using WHO data. <h3>Results</h3> ADA was administered to 23,458 pts, representing 36,730.5 PYs of exposure. Serious infections were the most frequently reported serious AEs across indications with the greatest incidence in RA and CD trials (table). Overall malignancy SIRs for ADA-treated pts were as expected in the general population; SIR of lymphoma was elevated in RA pts, but within the range expected in RA pts without anti-TNF therapy. Non-melanoma skin cancer SIR was elevated in RA, Ps, and CD pts. In all indications, SMRs were lower than or equivalent to those expected in the general population. <h3>Conclusions</h3> These data provide support for the long-term safety of adalimumab in 6 immune-mediated inflammatory diseases, highlight individual differences in rates by disease populations, and demonstrate a safety profile consistent with known information about the anti-TNF class. <h3>Disclosure of Interest</h3> G. Burmester Grant/Research support from: Abbott, Essex/Schering-Plough, Novartis, Roche, Wyeth, Consultant for: Abbott, Essex/Schering-Plough, Novartis, Roche, R. Panaccione Grant/Research support from: Abbott, Axcan, Bristol-Myers Squibb, Centocor, Elan, Millennium, Procter &amp; Gamble, Consultant for: Abbott, Astra-Zeneca, Bristol-Myers Squibb, Byk Solvay, Centocor, Elan, Ferring, GlaxoSmithKline, Janssen, Procter &amp; Gamble, Prometheus, Schering-Plough, Shire, UCB, K. Gordon Grant/Research support from: Abbott, Amgen, Centocor, Celgene, Consultant for: Abbott, Amgen, Centocor, Galderma, Lilly, Merck, Pfizer, M. McIlraith Shareholder of: Abbott, Employee of: Abbott, A. Lacerda Shareholder of: Abbott, Employee of: Abbott
Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy
Authors: Marie Overgaard, Per S. Hansen, Jens Overgaard, Carsten Rose, Michael Andersson, Flemming Bach, Mogens Kjaer, Carl C. Gadeberg, Henning T. Mouridsen, Maj-Britt Jensen, Karin Zedeler
Journal: New England Journal of Medicine (1997)

Irradiation after mastectomy can reduce locoregional recurrences in women with breast cancer, but whether it prolongs survival remains controversial. We conducted a randomized trial of radiotherapy after mastectomy in high-risk premenopausal women, all of whom also received adjuvant systemic chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF).
Abstract LB-130: The NCI-Nature Pathway Interaction Database: A cell signaling resource
Authors: Carl F. Schaefer, Kira Anthony, Mhairi A. Skinner, Jeffrey R. Buchoff, Matthew Day, Kenneth H. Buetow
Journal: Cancer Research (2010)

Abstract The NCI-Nature Pathway Interaction Database (PID, http://pid.nci.nih.gov) is a freely available collection of professionally curated and expert-reviewed signaling and regulatory pathways composed of human molecular interactions, signaling events and cellular processes extracted from primary literature. Pathways selected for curation are based on potential drug targets, suggestions made by our users and reviewers, and other prominent cell signaling molecules. As of February 2010, the database contains 106 pathways encompassing 6696 interactions, 3231 proteins, 142 small molecules, 2622 complexes and 4843 peer-reviewed publications, and includes recent additions to both the p53 and EGFR pathways. Created in a collaboration between the U.S. National Cancer Institute and Nature Publishing Group, the PID is aimed at researchers interested in cell signaling pathways, such as molecular cell biologists, and bioinformaticians. The database offers a range of tools to facilitate pathway exploration. Users can browse the pre-defined set of pathways and create network maps centered on a single molecule or biological process of interest. The Batch query tool allows users to upload molecule lists, such as those derived from microarray data, and visualize the resulting molecular connectivity map. In addition, users can download lists of proteins, references used to create the pathway and complete database content in extensible markup language (XML) or Biological Pathways Exchange (BioPAX) format. The database is updated every month and supplemented by a concise editorial section that provides synopses of recent noteworthy papers in cell signaling and specially commissioned articles on the practical uses of other relevant Bioinformatics tools. Users can sign up for email alerts or RSS feeds to receive database updates. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-130.
THE FIRST UNITED STATES EXPERIENCE IN NORMAL HUMAN MYOCARDIAL IMAGING WITH Tc-99m METHOXY ISOBUTYL ISONITRILE (RP-30).
Authors: J. Maddahi, L. Roy, K. Van Train, D. Brown, G. Nassar, W. Martwick, B. Woods, R. McLurkin, R. Merz, A. Waxman, D. Berman
Journal: Clinical Nuclear Medicine (1986)

Maddahi, J.; Roy, L.; Van Train, K.; Brown, D.; Nassar, G.; Martwick, W.; Woods, B.; McLurkin, R.; Merz, R.; Waxman, A.; Berman, D. Author Information
Managing Primary Care in the United States and in the United Kingdom
Authors: Kevin Grumbach, John Fry
Journal: New England Journal of Medicine (1993)

The United States is in the process of rediscovering primary care. Primary care is being promoted as an antidote to excessive health care costs and inadequate access to health services. However, primary care physicians in the United States are perceived to be in short supply, and their number is dwindling1,2. Only one third of the active physicians in the United States are family physicians, general internists, or general pediatricians, as compared with more than half of those in Canada and Western Europe3. The crisis in American health care has led to interest in other national health systems, . . .
Continuous increase in HIV-1 incidence after the year 2000 among men who have sex with men in Rome: insights from a 25-year retrospective cohort study
Authors: M Giuliani, M F Vescio, A Latini, G Palamara, F Pimpinelli, M G Donà, F Stivali, F Carduccelli, F Ensoli, A Di Carlo, G Rezza
Journal: Eurosurveillance (2014)

Binary file ES_Abstracts_Final_ECDC.txt matches
AB0010 Flow cytometry and pcr-sso in the determination of hla-b27 in the daily practice
Authors: M. Sanchez, V. Bermejo, C. Serrano, R. Gonzalo, S. Castañon, O. Calabia, P. Llorente, O. Sanchez, R. Garcia
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The determination of HLA-B27 antigen is a useful tool in the diagnosis of different inflammatory rheumatic diseases, being the association with ankylosing spondylitis (AS) the most frequent. The techniques used for this determination are microlymphocytotoxicity test, flow cytometry assay (FCM) and polymerase chain reaction sequence-specific oligonucleotide (PCR-SSO), being the last one the most accurate determination. <h3>Objectives</h3> As FCM rends some indeterminate results, the objective of the present work is to identify by PCR-SSO, the alleles of HLA-B gene that give indeterminate results in FCM. Also, to study the most common diagnosisassociated with HLA-B27 in our cohort of patients. <h3>Methods</h3> In 1110 samples from patients studied in the Rheumatology Unit of Fundación Jiménez Díaz-Capio during a year, the determination of HLA-B27 was performed in whole peripheral blood by FCM in a FACS Canto II cytometer (BD Biosciences, USA), using two different monoclonal antibodies: HLA-B27 (FITC) / HLA-B7 (PE) from Beckman Coulter and HLA-B27 (FITC) from One Lambda. Grafics were analyzed with <i>Infinicyt software</i> (Cytognos, Spain) The HLA-B27 typing was performed by PCR-SSO (INNO-LIPA, HLA-B Innogenetics, Belgium). <h3>Results</h3> 13,4% (149) of patients were positive HLA-B27 by FCM. 1,9% (22) patients that were indeterminate by FCM were evaluated by PCR-SSO. Of these 22 patients, 12,8% (5) were HLA-B27 positive. The frequency of alleles found in HLA-B27 negative by PCR-SSO were: B44 (20,5%), B18 (10,3%), B35 (10,3%), B8 (7,7%), B51 (7,7%), B7 (5,1%), as well as B15, B37 and B49. Only 18% of HLA-B27 positive patients were diagnosed of ankylosing spondylitis (AS) followed by 14% with undifferentiated spondyloarthropathy, 12% with some type of pains, 9% with arthritis (inflammatory, microcrystalline or infectious), 8% of uveitis and the rest of patients with a miscellaneous. <h3>Conclusions</h3> The more frequents alleles of HLA-B that give indeterminate results in the determination of HLA-B27 by FCM, were B44 allele, B18 and B35. FCM is proposed as a useful assay in the screening of the HLA-B27 antigen in the daily practice due its high performance (98,01%). For borderline cases, PCR-SSO is the recommended tool. <h3>References</h3> A high-resolution polymerase chain reaction-sequence-specific primer HLA-B*27 typing set and its application in routine HLA-B27 testing. Downing J, Coates E, Street J, Hammond L, Rees TJ, Pepperall J, Darke C.Genet Test. 2006 Summer;10(2):98-103. <h3>Disclosure of Interest</h3> None Declared
Association of Insufficient Sleep With Respiratory Infection Among Adults in the United States
Authors: Aric A. Prather, Cindy W. Leung
Journal: JAMA Internal Medicine (2016)

95% CI, 10.7%-10.7%),and 1-star hospitals with a rate of 11.2% (95% CI, 11.2%-11.3%)(P <.001 for trend).Higher CMS star ratings were also associated with lower adjusted readmission rates, with 5-star hospitals having the lowest readmissions rate of 18.7% (95% CI, 18.6%-18.8%),followed by 4-star hospitals with a rate of 20.2 (95% CI, 20.2%-20.2%),3-star hospitals with a rate of 21.0% (95% CI, 21.0%-21.0%),2-star hospitals with a rate of 21.8% (95% CI, 21.7%-21.8%),and 1-star hospitals with a rate of 22.9% (95% CI, 22.8%-22.9%)(P <.001 for trend) (Table 2).Discussion | We found that a higher CMS star rating was associated with lower patient mortality and readmissions.It is reassuring that patients can use the star ratings in guiding their health care seeking decisions given that hospitals with more stars not only offer a better experience of care, but also have lower mortality and readmissions.Our study has limitations.First, our analyses focused on the Medicare population; therefore, whether these findings would hold for younger patients is unclear.Second, although we adjusted for both patient and hospital characteristics, it is possible that some of the worse outcomes at low stars hospitals may represent residual confounding.Finally, the differences were most apparent at the extremes, with 2-to 4-star hospitals being relatively comparable.Whether this reflects the clustering methodology of the star rating program or whether quality of care is similar in these hospitals is unclear.These findings should be encouraging for policymakers and consumers; choosing 5-star hospitals does not seem to lead to worse outcomes and in fact may be driving patients to better institutions.
NATURAL HISTORY OF CORONARY ARTERIAL REMODELING IN PATIENTS WITH ACUTE CORONARY SYNDROME: A SERIAL INTRAVASCULAR ULTRASOUND STUDY
Authors: Jinwei Tian, Haibo Jia, Yoshiyasu Minami, Lei Gao, Hang Lee, Bo Yu, Ik-Kyung Jang
Journal: Journal of the American College of Cardiology (2015)
The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter
Authors: David A. Katzenstein, Scott M. Hammer, Michael D. Hughes, Holly Gundacker, J. Brooks Jackson, Susan Fiscus, Suraiya Rasheed, Tarek Elbeik, Richard Reichman, Anthony Japour, Thomas C. Merigan, Martin S. Hirsch
Journal: New England Journal of Medicine (1996)

We studied measures of human immunodeficiency virus (HIV) replication, the viral phenotype, and immune function (CD4 cell counts) and the relation of changes in these indicators to clinical outcomes in a subgroup of patients in a controlled trial of early antiretroviral treatment for HIV, the AIDS Clinical Trials Group Study 175.
Serial Liver-Function and Blood Studies in Patients Receiving Chlorpromazine
Authors: Robert Dickes, Victor Schenker, Lawrence Deutsch
Journal: New England Journal of Medicine (1957)

SIGNS of hepatic dysfunction have been observed in patients treated with chlorpromazine. There have been no reported attempts to follow, systematically, the changes in liver-function tests in patients receiving chlorpromazine, nor have there been reports of serial studies concerning hematologic changes. The literature on chlorpromazine-induced liver injury has recently been reviewed by Movitt et al.1 We therefore undertook serial studies to determine the course of changes in the liver function and in the blood morphology of patients treated with chlorpromazine. Fifty acutely disturbed, psychotic patients from the wards of Kings County Hospital were studied. Twenty-two of these were men between . . .
Genetic Analysis of an Inherited Predisposition to Colon Cancer in a Family with a Variable Number of Adenomatous Polyps
Authors: Mark Leppert, Randall Burt, J.P. Hughes, Wade Samowitz, Yusuke Nakamura, Scott Woodward, Eldon Gardner, Jean-Marc Lalouel, Ray White
Journal: New England Journal of Medicine (1990)

We studied a large kindred with a history of colorectal cancer of early onset. Proctosigmoidoscopic examination of 51 family members identified only 2 with familial polyposis coli, which strongly predisposes those who have it to colorectal cancer and which is defined as the presence of more than 100 polyps in the colon. However, eight family members had 2 to 40 colonic polyps. We suspected that in this family, colorectal cancer was the result of a mutation in the gene on chromosome 5 that is responsible for familial polyposis coli.